The findings from this study suggest that although these patients share a common PND antibody biomarker (CV2/CRMP5‐IgG), outcomes are heterogenous (as are the clinical phenotypes) and driven by cancer type and CNS involvement. This evidence concerns the gene DPYSL5 and cancer.